雌激素受体与卵巢癌SKOV3细胞顺铂耐药的相关性研究

发布时间：2018-03-03 01:22

本文选题：卵巢癌　切入点：雌激素受体　出处：《中国临床药理学杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的探讨雌激素受体与卵巢癌SKOV3细胞顺铂耐药的相关性。方法将4×106个SKOV3细胞接种于30只裸鼠大腿皮下构建人卵巢癌细胞系SKOV3异种移植瘤模型,并随机分为对照组15只和实验组15只。对照组予以0.9%Na Cl,每周1次,共给药5次,腹腔注射;实验组予以顺铂20 mg·kg~(-1),每周1次,共给药5次,腹腔注射。再从对照组和实验组上获得卵巢癌移植瘤SKOV3细胞。用免疫细胞化学法和流式细胞术检测SKOV3细胞中雌激素受体的表达水平;用噻唑蓝(MTT)法和流式细胞术分别检测不同浓度顺铂(0,1,5,10,15,20μg·m L~(-1))和雌激素受体抑制药ICI182(0,1,5,10,20μmol·L~(-1))单独及联合应用对SKOV3细胞的增殖及凋亡的影响。结果实验组和对照组的免疫细胞化学评分(HIS值)分别为(10.04±2.93),(6.73±2.37)分;雌激素受体表达分别为231.39±15.33,205.81±12.50,差异均有统计学意义(P0.01)。ICI182对对照组、实验组细胞均表现为增殖抑制,呈现剂量-时间依赖关系;随着顺铂浓度的升高,10μmol·L~(-1)ICI182联合顺铂作用SKOV3细胞时抑制作用显著增强,差异有统计学意义(P0.01)。实验组和对照组分别用10μmol·L~(-1)ICI182+10μg·m L~(-1)顺铂处理后,其细胞凋亡率分别为(70.07±0.64)%和(82.13±0.87)%,差异有统计学意义(P0.01)。结论雌激素受体参与了化疗耐药过程,通过ICI182抑制雌激素受体蛋白可能逆转卵巢癌细胞的顺铂耐药。
[Abstract]:Objective to investigate the relationship between estrogen receptor and SKOV3 ovarian cancer cells resistant to cisplatin. Methods 4 x 106 SKOV3 cells were inoculated to build SKOV3 xenograft model of human ovarian cancer cell line 30 mice thigh subcutaneous, and were randomly divided into control group 15 and experimental group 15. Control group was treated with 0.9%Na Cl, 1 times a week a total of 5 times, administration, intraperitoneal injection; experimental group received cisplatin 20 mg - kg~ (-1), 1 times a week, a total of 5 times administration, intraperitoneal injection. The control group and the experimental group was transplanted ovarian cancer cells SKOV3. The expression level of estrogen receptor and flow cytometry in detection of SKOV3 cells by immunocytochemical method; by tetrazolium (MTT) assay and flow cytometry were used to detect different concentrations of cisplatin (0,1,5,10,15,20 g m L~ (-1)) and estrogen receptor inhibitor ICI182 (0,1,5,10,20 mol L~ (-1)) alone or in combination on proliferation and apoptosis of SKOV3 cells. Shadow The results of immunocytochemical ring. The experimental group and the control group score (HIS) respectively (10.04 + 2.93), (6.73 + 2.37); the expression of estrogen receptor were 231.39 + 15.33205.81 + 12.50, the differences were statistically significant (P0.01.ICI182) in the control group, the experimental group cells showed inhibition of proliferation. A dose time dependent manner; with increasing cisplatin concentration, 10 mol - L~ (-1) ICI182 combined with cisplatin in SKOV3 cells inhibited significantly increased, the difference was statistically significant (P0.01). The experimental group and the control group were treated with 10 mol L~ (-1) ICI182+10 g m L~ (-1) after treatment with cisplatin, the cell apoptosis rate was (70.07 + 0.64)% and (82.13 + 0.87)%, the difference was statistically significant (P0.01). Conclusion estrogen receptors are involved in the process of drug resistance during chemotherapy, through ICI182 inhibition of estrogen receptor protein can reverse cisplatin resistance to ovarian cancer cells.

【作者单位】：唐山市工人医院产科;
【基金】：河北省医学科学研究重点课题基金资助项目(ZD20140384)
【分类号】：R737.31

【参考文献】